IL147921A0 - A method for treating central nervous system disorders by ocular dosing - Google Patents

A method for treating central nervous system disorders by ocular dosing

Info

Publication number
IL147921A0
IL147921A0 IL14792102A IL14792102A IL147921A0 IL 147921 A0 IL147921 A0 IL 147921A0 IL 14792102 A IL14792102 A IL 14792102A IL 14792102 A IL14792102 A IL 14792102A IL 147921 A0 IL147921 A0 IL 147921A0
Authority
IL
Israel
Prior art keywords
nervous system
central nervous
system disorders
treating central
ocular dosing
Prior art date
Application number
IL14792102A
Original Assignee
Abdulrazik Mohammad
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abdulrazik Mohammad filed Critical Abdulrazik Mohammad
Priority to IL14792102A priority Critical patent/IL147921A0/en
Publication of IL147921A0 publication Critical patent/IL147921A0/en
Priority to US10/354,173 priority patent/US20030181354A1/en
Priority to US11/951,748 priority patent/US20080131483A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
IL14792102A 2002-01-31 2002-01-31 A method for treating central nervous system disorders by ocular dosing IL147921A0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
IL14792102A IL147921A0 (en) 2002-01-31 2002-01-31 A method for treating central nervous system disorders by ocular dosing
US10/354,173 US20030181354A1 (en) 2002-01-31 2003-01-30 Method for central nervous system targeting through the ocular route of drug delivery
US11/951,748 US20080131483A1 (en) 2002-01-31 2007-12-06 Enhancement of Drug Delivery to the Central Nervous System

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL14792102A IL147921A0 (en) 2002-01-31 2002-01-31 A method for treating central nervous system disorders by ocular dosing

Publications (1)

Publication Number Publication Date
IL147921A0 true IL147921A0 (en) 2002-08-14

Family

ID=27840268

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14792102A IL147921A0 (en) 2002-01-31 2002-01-31 A method for treating central nervous system disorders by ocular dosing

Country Status (2)

Country Link
US (2) US20030181354A1 (en)
IL (1) IL147921A0 (en)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1305294B1 (en) 1999-01-29 2001-05-04 Alessandro Lambiase USE OF THE NERVE GROWTH FACTOR IN THE THERAPY OF PATHOLOGIES DEPENDING ON INTRAOCULAR TISSUES.
DE60024855T2 (en) 1999-10-29 2006-08-31 Orion Corp. USE OF AN IMIDAZOLE DERIVATIVE FOR THE TREATMENT OR PREVENTION OF HYPOTENSION AND SHOCK
US20040266776A1 (en) * 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
AU2003257418A1 (en) * 2002-06-19 2004-01-06 Solvay Pharmaceuticals Gmbh Medicament for the treatment of diseases requiring inhibition or a reduction in the activity of ph value-regulating bicarbonate transporter proteins
ITRM20050447A1 (en) * 2005-08-19 2007-02-20 Anabasis S R L USE OF THE NERVE GROWTH FACTOR IN COLLIRIUM IN THE PATHOLOGY OF THE CENTRAL NERVOUS SYSTEM, SUCH AS ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE.
BRPI0706759A2 (en) * 2006-01-27 2011-04-05 Hofmann La Roche Ag F USE OF 4-IMIDAZOL DERIVATIVES FOR CNS DISORDERS
JP2009524619A (en) * 2006-01-27 2009-07-02 エフ．ホフマン−ラ ロシュ アーゲー Use of 2-imidazole for the treatment of CNS disorders
EP1981499A1 (en) * 2006-01-27 2008-10-22 F.Hoffmann-La Roche Ag Use of 2-imidazoles for the treatment of cns disorders
WO2007111806A2 (en) 2006-03-23 2007-10-04 Massachusetts Eye And Ear Infirmary Cyclopentane heptanoic acid compounds for reducing body fat
EP2076497B1 (en) * 2006-10-19 2012-02-22 F. Hoffmann-La Roche AG Aminomethyl-4-imidazoles
BRPI0718059A2 (en) * 2006-10-19 2013-11-05 Holffmann La Roche Ag F AMINOMETIL-2-IMIDAZOOS WITH AFFINITY WITH AMINE-ASSOCIATED TRACE RECEIVERS
EP2086959B1 (en) 2006-11-02 2011-11-16 F. Hoffmann-La Roche AG Substituted 2-imidazoles as modulators of the trace amine associated receptors
KR101134226B1 (en) * 2006-11-16 2012-04-10 에프. 호프만-라 로슈 아게 Substituted 4-imidazoles
KR101189348B1 (en) * 2006-12-13 2012-10-09 에프. 호프만-라 로슈 아게 Novel 2-imidazoles as ligands for trace amine associated receptorstaar
US20080146523A1 (en) 2006-12-18 2008-06-19 Guido Galley Imidazole derivatives
FR2911329B1 (en) * 2007-01-12 2009-04-17 Rexam Pharma Soc Par Actions S PACKAGING AND DISPENSING ASSEMBLY OF A MEDICAL LIQUID
PL2117524T3 (en) * 2007-01-29 2020-03-31 National Research Council Of Canada Use of catecholamines and related compounds as anti-angiogenic agents
KR101174191B1 (en) 2007-02-02 2012-08-14 에프. 호프만-라 로슈 아게 Novel 2-aminooxazolines as taar1 ligands for cns disorders
JP5130305B2 (en) * 2007-02-15 2013-01-30 エフ．ホフマン−ラ ロシュ アーゲー 2-Aminooxazoline as a TAAR1 ligand
EP2173720A2 (en) 2007-07-02 2010-04-14 F. Hoffmann-Roche AG 2-imidazolines having a good affinity to the trace amine associated receptors (taars)
AU2008270444A1 (en) * 2007-07-03 2009-01-08 F. Hoffmann-La Roche Ag 4-imidazolines and their use as antidepressants
KR101133862B1 (en) * 2007-07-27 2012-04-06 에프. 호프만-라 로슈 아게 2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as taar-ligands
US20100310473A1 (en) * 2007-07-30 2010-12-09 The General Hospital Corporation Targeting Brain Cells Via Ophthalmic Delivery
CA2695071A1 (en) * 2007-08-02 2009-02-05 F. Hoffmann-La Roche Ag The use of benzamide derivatives for the treatment of cns disorders
EP2185502A1 (en) * 2007-08-03 2010-05-19 F. Hoffmann-Roche AG Pyridinecarboxamide and benzamide derivatives as taar1 ligands
IL186598A0 (en) * 2007-10-11 2008-11-03 Mohammad Abdulrazik Composition and method for the treatment or prevention of glaucoma and ocular hypertension
WO2009103150A1 (en) * 2008-02-20 2009-08-27 Kevin David Smith Method for treating migraine headaches
TNSN08110A1 (en) * 2008-03-11 2009-07-14 Rekik Raouf Dr Drug delivery to the anterior and posterior segment of the eye from drops
US7795263B2 (en) * 2008-07-08 2010-09-14 Wildlife Laboratories, Inc. Pharmaceutical combination for and method of anesthetizing and immobilizing non-domesticated mammals
WO2010010014A1 (en) * 2008-07-24 2010-01-28 F. Hoffmann-La Roche Ag 4,5-dihydro-oxazol-2-yl derivatives
US8242153B2 (en) * 2008-07-24 2012-08-14 Hoffmann-La Roche Inc. 4,5-dihydro-oxazol-2YL derivatives
US20100203165A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
US8952011B2 (en) 2008-08-01 2015-02-10 Eye Therapies Llc Compositions and methods for the treatment of nasal conditions
SI2320911T1 (en) 2008-08-01 2014-12-31 Eye Therapies Llc Vasoconstriction compositions and methods of use
WO2010065547A1 (en) * 2008-12-01 2010-06-10 Map Pharmaceuticals, Inc. Inhalation delivery methods and devices
WO2010074753A1 (en) 2008-12-23 2010-07-01 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
CN102421479A (en) 2009-02-26 2012-04-18 北卡罗来纳大学查珀尔希尔分校 Interventional drug delivery system and associated methods
NZ596976A (en) * 2009-05-15 2014-05-30 Recro Pharma Inc Sublingual dexmedetomidine compositions and methods of use thereof
US20100311798A1 (en) * 2009-06-05 2010-12-09 Decoret Guillaume 2-aminooxazolines as taar1 ligands
US8987270B2 (en) 2009-07-27 2015-03-24 Eye Therapies Llc Formulations of selective alpha-2 agonists and methods of use thereof
US20110097380A1 (en) * 2009-10-28 2011-04-28 Warsaw Orthopedic, Inc. Clonidine formulations having antimicrobial properties
US8354441B2 (en) * 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
WO2011075621A1 (en) * 2009-12-17 2011-06-23 Alpha Synergy Development, Inc. Compositions and methods for ophthalmic delivery of nasal decongestants
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
JP2013516482A (en) * 2010-01-08 2013-05-13 レクロ・ファーマ，インコーポレーテッド Topical transdermal dexmedetomidine compositions and methods for their use
EP2608794A4 (en) * 2010-08-26 2014-01-22 Univ Northeastern Methods and compositions for preventing or treating obesity
JP5778781B2 (en) 2011-01-19 2015-09-16 トポカイン セラピューティックス， インコーポレイテッド Methods and compositions for treating metabolic syndrome
US9259409B2 (en) * 2011-01-24 2016-02-16 Inceptum Research & Therapeutics, Inc. Compositions comprising a prostaglandin for treating neuropsychiatric conditions
US8445526B2 (en) 2011-02-03 2013-05-21 Glaucoma & Nasal Therapies Llc Compositions and methods for treatment of glaucoma
EP3406247A1 (en) 2011-12-11 2018-11-28 Recro Pharma, Inc. Intranasal dexmedetomidine compositions and methods of use thereof
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
JP5877620B2 (en) 2012-11-21 2016-03-08 トポカイン セラピューティックス， インコーポレイテッド Methods and compositions for locally increasing body fat
WO2014138298A1 (en) * 2013-03-05 2014-09-12 University Of Chicago Treatment of demyelinating disorders
NO2753788T3 (en) 2013-05-10 2018-06-16
US9820993B2 (en) 2013-05-15 2017-11-21 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
US8999938B2 (en) 2013-06-21 2015-04-07 Gnt Llc Ophthalmic lipophilic drug delivery vehicle formulations
US10188661B2 (en) 2014-06-27 2019-01-29 Topokine Therapeutics, Inc. Topical dosage regimen
US9937074B2 (en) 2015-01-22 2018-04-10 Eyegate Pharmaceuticals, Inc. Iontophoretic contact lens
MA53755A (en) 2016-03-17 2021-08-04 Hoffmann La Roche 5-ETHYL-4-METHYL-PYRAZOLE-3-CARBOXAMIDE DERIVATIVE WITH TAAR AGONIST ACTIVITY
KR101844816B1 (en) * 2017-02-27 2018-04-04 울산대학교 산학협력단 Composition For Improving Or Treating Anorexia Including Guanabenz And Method Using Thereof
NZ766141A (en) 2017-12-15 2024-01-26 Tarsus Pharmaceuticals Inc Isoxazoline parasiticide formulations and methods for treating blepharitis
CN110559285B (en) * 2019-09-23 2020-06-26 佳木斯大学 Pharmaceutical composition for preventing or treating cerebral ischemia-reperfusion injury and preparation method thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610720B2 (en) * 2000-08-24 2003-08-26 Merck Frosst Canada & Co. Method for treating or preventing emesis
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists

Also Published As

Publication number Publication date
US20030181354A1 (en) 2003-09-25
US20080131483A1 (en) 2008-06-05

Similar Documents

Publication Publication Date Title
IL147921A0 (en) A method for treating central nervous system disorders by ocular dosing
AU2003297761A1 (en) Methods for treating neurological language disorders
PL373626A1 (en) Treatment for central nervous system disorders
EP1545700A4 (en) Methods for treating central nervous system damage
AU2003249983A8 (en) Piperidines useful for the treatment of central nervous system disorders
EP1572075A4 (en) Method for treating diseases associated with abnormal kinase activity
AU2003272713A8 (en) A method for treating severe tinnitus
EP1476147A4 (en) Methods for treating eye disorders
PL1655036T3 (en) Method for treating oncological diseases
IL178648A0 (en) Substituted morpholine compounds for the treatment of central nervous system disorders
IL175818A0 (en) Method for treating adamts-5- associated disease
EP1328186A4 (en) Methods for treating various eye disorders
IL180732A0 (en) Method for treating nervous system disorders and conditions
EP1695061A4 (en) Method for treating neurological disorders
MXPA03006607A (en) Combined method for treating hormono-dependent disorders.
ZA200700578B (en) Method for treating nervous system disorders and conditions
IL163993A0 (en) Method for treating cognitive disorders
GB0422769D0 (en) Methods for treating deodorizer distillate
AU2003247384A8 (en) Methods for treating a neurological disorder by peripheral administration of a trophic factor
AU2002359459A8 (en) Treating b-cell mediated diseases by modulating dr6 activity
ZA200700580B (en) Method for treating nervous system disorders and conditions
AU2003228813A8 (en) Methods for treating neuronal disorders
AU2003248775A8 (en) Oligonucleotides for treating proliferative disorders
AU2002229795A1 (en) Method for treating sexual disorders
GB0324853D0 (en) Apparatus for treating movement disorders